AB Science announces that AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA
November 07, 2019 02:26 ET
|
AB Science
Paris, November 7, 2019, 8.30am AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA AB Science SA (NYSE Euronext - FR0010557264 - AB) announces today that the U.S. Food and...
AB Science annonce la première présentation de résultats précliniques de la molécule AB8939 au 61eme congrès annuel de l'American Society of Hematology (ASH)
November 06, 2019 16:21 ET
|
AB Science
Paris, 6 novembre 2019, 22h AB Science annonce la première présentation de résultats précliniquesde la molécule AB8939 au 61eme congrès annuel de l'American Society of Hematology (ASH) AB Science SA...
AB Science announces the first presentation of preclinical results for compound AB8939 in the 61st ASH Annual Meeting online program
November 06, 2019 16:21 ET
|
AB Science
Paris, November 6, 2019, 10pm AB Science announces the first presentation of preclinical results forcompound AB8939 in the 61st ASH Annual Meeting online program AB Science...
Incysus Therapeutics to Present at the 2019 Bio Investor Forum
October 22, 2019 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2019 16:07 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 30, 2019 16:08 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September
August 28, 2019 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement
August 21, 2019 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
CORRECTING and REPLACING - Bellicum Pharmaceuticals, Inc.
August 16, 2019 10:52 ET
|
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement Pricing of $57.5 Million Public Offering of Preferred Stock and Warrants and Entry into Concurrent...
Bellicum Pharmaceuticals Announces Pricing of Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement
August 16, 2019 08:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...